vs
Guardant Health, Inc.（GH）与Ribbon Communications Inc.（RBBN）财务数据对比。点击上方公司名可切换其他公司
Guardant Health, Inc.的季度营收约是Ribbon Communications Inc.的1.7倍（$281.3M vs $162.6M），Ribbon Communications Inc.净利率更高（54.8% vs -45.7%，领先100.5%），Guardant Health, Inc.同比增速更快（39.4% vs -10.3%），过去两年Guardant Health, Inc.的营收复合增速更高（29.2% vs -8.1%）
Guardant Health, Inc.是总部位于美国加利福尼亚州帕洛阿尔托的生物技术企业，由Helmy Eltoukhy与AmirAli Talasaz联合创立，目前二人共同出任公司首席执行官，统筹公司战略规划与日常运营管理工作。
睿宾通信公司（Ribbon Communications Inc.）主要为电信运营商、企业及关键基础设施领域提供软件、IP与光网络解决方案。公司于2017年由Genband与Sonus Networks合并成立，总部位于美国得克萨斯州普莱诺，是一家上市科技企业。
GH vs RBBN — 直观对比
营收规模更大
GH
是对方的1.7倍
$162.6M
营收增速更快
GH
高出49.7%
-10.3%
净利率更高
RBBN
高出100.5%
-45.7%
两年增速更快
GH
近两年复合增速
-8.1%
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $281.3M | $162.6M |
| 净利润 | $-128.5M | $89.1M |
| 毛利率 | 64.6% | 42.9% |
| 营业利润率 | -43.0% | 37.6% |
| 净利率 | -45.7% | 54.8% |
| 营收同比 | 39.4% | -10.3% |
| 净利润同比 | -15.8% | — |
| 每股收益（稀释后） | $-1.01 | $0.50 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收GHRBBN
| Q1 26 | — | $162.6M | ||
| Q4 25 | $281.3M | $227.3M | ||
| Q3 25 | $265.2M | $215.4M | ||
| Q2 25 | $232.1M | $220.6M | ||
| Q1 25 | $203.5M | $181.3M | ||
| Q4 24 | $201.8M | $251.4M | ||
| Q3 24 | $191.5M | $210.2M | ||
| Q2 24 | $177.2M | $192.6M |
净利润GHRBBN
| Q1 26 | — | $89.1M | ||
| Q4 25 | $-128.5M | — | ||
| Q3 25 | $-92.7M | $-12.1M | ||
| Q2 25 | $-99.9M | $-11.1M | ||
| Q1 25 | $-95.2M | $-26.2M | ||
| Q4 24 | $-111.0M | — | ||
| Q3 24 | $-107.8M | $-13.4M | ||
| Q2 24 | $-102.6M | $-16.8M |
毛利率GHRBBN
| Q1 26 | — | 42.9% | ||
| Q4 25 | 64.6% | 53.3% | ||
| Q3 25 | 64.7% | 50.1% | ||
| Q2 25 | 65.0% | 49.6% | ||
| Q1 25 | 63.3% | 45.4% | ||
| Q4 24 | 61.6% | 55.7% | ||
| Q3 24 | 61.1% | 52.1% | ||
| Q2 24 | 59.1% | 50.8% |
营业利润率GHRBBN
| Q1 26 | — | 37.6% | ||
| Q4 25 | -43.0% | 4.1% | ||
| Q3 25 | -37.3% | 1.3% | ||
| Q2 25 | -45.9% | 1.9% | ||
| Q1 25 | -54.6% | -10.8% | ||
| Q4 24 | -62.4% | 13.2% | ||
| Q3 24 | -61.3% | -0.4% | ||
| Q2 24 | -56.8% | -1.0% |
净利率GHRBBN
| Q1 26 | — | 54.8% | ||
| Q4 25 | -45.7% | — | ||
| Q3 25 | -35.0% | -5.6% | ||
| Q2 25 | -43.0% | -5.0% | ||
| Q1 25 | -46.8% | -14.5% | ||
| Q4 24 | -55.0% | — | ||
| Q3 24 | -56.3% | -6.4% | ||
| Q2 24 | -57.9% | -8.7% |
每股收益（稀释后）GHRBBN
| Q1 26 | — | $0.50 | ||
| Q4 25 | $-1.01 | $0.50 | ||
| Q3 25 | $-0.74 | $-0.07 | ||
| Q2 25 | $-0.80 | $-0.06 | ||
| Q1 25 | $-0.77 | $-0.15 | ||
| Q4 24 | $-0.90 | $0.05 | ||
| Q3 24 | $-0.88 | $-0.08 | ||
| Q2 24 | $-0.84 | $-0.10 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $378.2M | $67.6M |
| 总债务越低越好 | $1.5B | — |
| 股东权益账面价值 | $-99.3M | $419.1M |
| 总资产 | $2.0B | — |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资GHRBBN
| Q1 26 | — | $67.6M | ||
| Q4 25 | $378.2M | $96.4M | ||
| Q3 25 | $580.0M | $74.8M | ||
| Q2 25 | $629.1M | $60.5M | ||
| Q1 25 | $698.6M | $71.2M | ||
| Q4 24 | $525.5M | $87.8M | ||
| Q3 24 | $585.0M | $37.2M | ||
| Q2 24 | $933.7M | $64.6M |
总债务GHRBBN
| Q1 26 | — | — | ||
| Q4 25 | $1.5B | $342.1M | ||
| Q3 25 | $1.1B | $344.3M | ||
| Q2 25 | $1.1B | $346.5M | ||
| Q1 25 | $1.1B | $347.4M | ||
| Q4 24 | $1.1B | $348.3M | ||
| Q3 24 | — | $349.1M | ||
| Q2 24 | — | $350.0M |
股东权益GHRBBN
| Q1 26 | — | $419.1M | ||
| Q4 25 | $-99.3M | $449.0M | ||
| Q3 25 | $-354.5M | $360.1M | ||
| Q2 25 | $-305.5M | $370.4M | ||
| Q1 25 | $-250.8M | $381.8M | ||
| Q4 24 | $-139.6M | $404.6M | ||
| Q3 24 | $-60.1M | $395.5M | ||
| Q2 24 | $-1.6M | $405.0M |
总资产GHRBBN
| Q1 26 | — | — | ||
| Q4 25 | $2.0B | $1.2B | ||
| Q3 25 | $1.3B | $1.1B | ||
| Q2 25 | $1.3B | $1.1B | ||
| Q1 25 | $1.3B | $1.1B | ||
| Q4 24 | $1.5B | $1.2B | ||
| Q3 24 | $1.5B | $1.1B | ||
| Q2 24 | $1.6B | $1.1B |
负债/权益比GHRBBN
| Q1 26 | — | — | ||
| Q4 25 | — | 0.76× | ||
| Q3 25 | — | 0.96× | ||
| Q2 25 | — | 0.94× | ||
| Q1 25 | — | 0.91× | ||
| Q4 24 | — | 0.86× | ||
| Q3 24 | — | 0.88× | ||
| Q2 24 | — | 0.86× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-26.4M | — |
| 自由现金流经营现金流 - 资本支出 | $-54.2M | — |
| 自由现金流率自由现金流/营收 | -19.3% | — |
| 资本支出强度资本支出/营收 | 9.9% | — |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-233.1M | — |
8季度趋势，按日历期对齐
经营现金流GHRBBN
| Q1 26 | — | — | ||
| Q4 25 | $-26.4M | $29.2M | ||
| Q3 25 | $-35.4M | $26.5M | ||
| Q2 25 | $-60.3M | $-795.0K | ||
| Q1 25 | $-62.7M | $-3.5M | ||
| Q4 24 | $-64.5M | $61.8M | ||
| Q3 24 | $-51.1M | $-14.8M | ||
| Q2 24 | $-94.0M | $-9.8M |
自由现金流GHRBBN
| Q1 26 | — | — | ||
| Q4 25 | $-54.2M | $27.3M | ||
| Q3 25 | $-45.8M | $21.0M | ||
| Q2 25 | $-65.9M | $-6.5M | ||
| Q1 25 | $-67.1M | $-15.7M | ||
| Q4 24 | $-83.4M | $53.8M | ||
| Q3 24 | $-55.3M | $-23.7M | ||
| Q2 24 | $-99.1M | $-12.9M |
自由现金流率GHRBBN
| Q1 26 | — | — | ||
| Q4 25 | -19.3% | 12.0% | ||
| Q3 25 | -17.3% | 9.7% | ||
| Q2 25 | -28.4% | -2.9% | ||
| Q1 25 | -33.0% | -8.7% | ||
| Q4 24 | -41.3% | 21.4% | ||
| Q3 24 | -28.9% | -11.3% | ||
| Q2 24 | -55.9% | -6.7% |
资本支出强度GHRBBN
| Q1 26 | — | — | ||
| Q4 25 | 9.9% | 0.9% | ||
| Q3 25 | 3.9% | 2.6% | ||
| Q2 25 | 2.4% | 2.6% | ||
| Q1 25 | 2.2% | 6.7% | ||
| Q4 24 | 9.4% | 3.2% | ||
| Q3 24 | 2.2% | 4.2% | ||
| Q2 24 | 2.9% | 1.6% |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
GH
| Oncology | $189.9M | 68% |
| Biopharma Data | $54.0M | 19% |
| Screening | $35.1M | 12% |
| Licensing Other | $2.2M | 1% |
RBBN
| Service | $94.5M | 58% |
| Product | $68.1M | 42% |
